



iTOC8

CONFERENCE

www.itoc-conference.eu

8TH IMMUNOTHERAPY
OF CANCER CONFERENCE

THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

8th ImmunoTherapy of Cancer Conference
October 8 - 9, 2021 • Virtual Conference

TUMORZENTRUM
MÜNCHEN



CCC MÜNCHEN
COMPREHENSIVE
CANCER CENTER



DKTK

Deutsches Konsortium für
Translationale Krebsforschung



CECOG ACADEMY
Central European Cooperative Oncology Group



SCIENTIFIC PROGRAM

TABLE OF CONTENTS

iTOC8 Committees.....	3
Live Talks.....	4 - 7
e-Poster Presentations.....	8 - 12
Scientific Information.....	13
Live Satellite Symposia.....	14 - 15
On-Demand Satellite Symposia.....	16
General Information.....	17 - 18
Acknowledgements.....	19

The 8th ImmunoTherapy of Cancer Conference (ITOC8) to be held virtually from October 8 - 9, 2021 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.



ITOC8 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TzM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON as well as the Comprehensive Cancer Center Munich (CCCM) in Munich. The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.



ITOC8 COMMITTEES

ITOC8 Conference President

- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

ITOC8 Chairman of the Scientific Committee

- Volkmar Nuessler (TZM, Munich, Germany)

ITOC8 Scientific Committee

- Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
- Paolo Ascierto (Istituto Nazionale Tumori, Naples, Italy)
- Michael Bergmann (Medical University Vienna, Austria)
- Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
- Rafal Dziadziuszko (Medical University of Gdańsk, Poland)
- Ulrich Jäger (Medical University of Vienna, Austria)
- Samir N. Khleif (Georgetown University Medical Center, Washington DC, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Maciej Krzakowski (Oncology Centre, Maria Skłodowska-Curie Institute, Warsaw, Poland)
- Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
- Sine Reker Hadrup (Technical University of Denmark, Experimental & Translational Immunology, Lyngby, Denmark)
- Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
- José Saro (Global Clinical Development, Adaptimmune Therapeutics, Abingdon, Oxfordshire, United Kingdom)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Maria Sibilía (Medical University of Vienna, Austria)
- Wenru Song (Kira Pharmaceuticals, Arlington, MA, United States)
- Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
- Mario Sznol (Yale School of Medicine, New Haven, CT, United States)
- Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France)
- Giorgio Trinchieri (Center for Cancer Research, NCI, NIH, Bethesda, MD, United States)
- Lei Zheng (Johns Hopkins University, Baltimore, MD, United States)
- Christoph Zielinski (Medical University of Vienna, Austria)



LIVE TALKS - FRIDAY, OCTOBER 8, 2021

08.30 – 08.40

Welcome Address

Michael von Bergwelt, Munich, Germany

08.40 – 10.00

Session 1: Emerging Concepts / New Agents

Chair: Pedro Romero and Christoph Zielinski

08.40 – 09.00

01.01 - T cell exhaustion

Dietmar Zehn, Munich, Germany

09.00 – 09.20

01.02 - Targets to upregulate STING and endogenous retroviruses in tumors

Marcus Bosenberg, New Haven, CT, USA

09.20 – 09.40

01.03 - Resident memory T cells in anti-tumor immunity

Fathia Mami-Chouaib, Paris, France

09.40 – 10.00

01.04 - Clever-1

Maija Hollmen, Turku, Finland

10.00 – 10.30

Coffee Break

10.30 – 11.50

Session 2: Tumor microenvironment and microbiome in Immunotherapy

Chair: Eric Tartour and Maria Sibilio

10.30 – 10.50

02.01 - T helper subsets in cancer control and progression

Samuel Huber, Hamburg, Germany

10.50 – 11.10

02.02 - Role of Tumor-intrinsic PD-L1 Signaling in Adaptive Resistance to Immunotherapy

Brent Hanks, Durham, NC, USA

11.10 – 11.30

02.03 - The role of the microbiome in cancer therapy

Meriem Messaoudene, Montréal, Canada

11.30 – 11.50

02.04 - Role of tertiary lymphoid structures in cancer biology

Tullia Bruno, Pittsburgh PA, USA

11.50 – 12.50

Lunch Break

12.50 – 13.20

Satellite Symposium - Please see page 14 for further information

13.20 – 14.40

Session 3: Vaccine Therapy

Chair: Paolo Ascierto and Barbara Seliger

13.20 – 13.40

03.01 - Unconventional Targets for Vaccine Therapies

Mads Hald Andersen, Copenhagen, Denmark

13.40 – 14.00

03.02 - Phase Ib trial with neoantigen-based vaccines in solid tumors

Patrick Ott, Boston, MA, USA



LIVE TALKS - FRIDAY, OCTOBER 8, 2021



14.00 – 14.20	03.03 - Shared Immunogenic Cancer Antigens in Humans and Combination Immunotherapy Clinical Trials that Exploit Those Antigens Bernard A. Fox, Portland, OR, USA
14.20 – 14.40	03.04 - Therapeutic vaccines against HPV associated cancers Toos Daemen, Groningen, The Netherlands
14.40 – 15.10	Coffee Break
15.10 – 15.50	Session 4: Pro & Contra Session Chair: Ulrich Jäger and Marion Subklewe
15.10 – 15.30	04.01 - CAR T in AML – bridge to transplant vs standalone therapy Saar Gill, Philadelphia, PA, USA
15.30 – 15.50	04.02 - Allogenic Stem Cell Transplantation in AML: Do we even need CAR T cells? Nicolaus Kröger, Hamburg, Germany
15.50 – 15.55	Short Break
15.55 – 17.15	Session 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring) Chair: Samir Khleif and Sine Reker Hadrup
15.55 – 16.15	05.01 - Novel targets to enhance the efficacy of immune checkpoint blockades X. Shirley Liu, Boston, MA, USA
16.15 – 16.35	05.02 - (De)classifying Human TILs to Promote immune Persistence and Predict Rational Therapeutics Niroshana Anandasabapathy, New York, NY, USA
16.35 – 16.55	05.03 - In situ immunophenotyping of tumor infiltrating T-cells to predict response to immune checkpoint inhibitors in kidney cancer Sabina Signoretti, Boston, MA, USA
16.55 – 17.15	05.04 - Spatially resolved and high-dimensional characterisation of tumour immune microenvironment remodelling following oncogene inhibition Febe van Maldegem, London, United Kingdom
17.15 – 17.20	Short Break
17.20 – 17.50	Satellite Symposium - Please see page 15 for further information
17.50 – 18.30	Session 6: "Lost in Translation"? Chair: Mario Sznol and Jose Saro
17.50 – 18.10	06.01 - Anti-cancer vaccines Cornelis Melief, Leiden, The Netherlands
18.10 – 18.30	06.02 - Next Generation Functional Drug Screening for Personalized Therapy Philipp Staber, Vienna, Austria




LIVE TALKS - SATURDAY, OCTOBER 9, 2021

08.00 – 09.20	<p>Session 7: Cell Therapy in Solid Tumors Chair: Michael Hudecek and Simon Heidegger</p>
08.00 – 08.20	<p>07.01 - Immunogenic chemotherapy for breaking resistance to CAR T cells in solid tumors Stanley Riddell, Seattle, WA, USA</p>
08.20 – 08.40	<p>07.02 - Redirecting CAR T cells to cancer tissue using chemokine receptors Sebastian Kobold, Munich, Germany</p>
08.40 – 09.00	<p>07.03 - Anti CD20 directed CAR T in Malignant Melanoma Michael von Bergwelt, Munich, Germany</p>
09.00 – 09.20	<p>07.04 - ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive solid tumors David S. Hong, Houston, TX, USA</p>
09.20 – 09.50	<p>We invite you to visit the virtual stands and on-demand symposia of our sponsors, as well as to view the e-poster presentations of your colleagues.</p>
09.50 – 10.20	<p>Coffee Break</p>
10.20 – 11.40	<p>Session 8: Cell Therapy in Haematologic Diseases Chair: Hinrich Abken and Anita Kremer</p>
10.20 – 10.40	<p>08.01 - Visualizing CAR T cells at work Philippe Bousso, Paris, France</p>
10.40 – 11.00	<p>08.02 - Dissecting CAR T cell resistance in lymphomas Marco Ruella, Philadelphia, PA, USA</p>
11.00 – 11.20	<p>08.03 - TCR transgenic T cells Dirk Busch, Munich, Germany</p>
11.20 – 11.40	<p>08.04 - CAR armed NK cells for cancer treatment May Daher, Houston, TX, USA</p>
11.40 – 12.15	<p>Session 9: Lifetime Achievement Award Chair: Christoph Zielinski and Michael von Bergwelt</p>
	<p>09.01 - Translating the success of the mRNA vaccine to cancer Speaker Uğur Şahin and Özlem Türeci, BioNtech SE, Mainz, Germany</p>



LIVE TALKS - SATURDAY, OCTOBER 9, 2021

12.15 – 13.00	Lunch Break
13.00 – 13.30	We invite you to visit the virtual stands and on-demand symposia of our sponsors, as well as to view the e-poster presentations of your colleagues.
13.30 – 14.50	Session 10: Young Researcher Session Chair: Volkmar Nüssler and Sebastian Kobold
13.30 – 13.50	10.01 - Effective solid tumor therapy through enhanced recruitment and immune suppression shielded T cells Bruno Cadilha, Munich, Germany
13.50 – 14.10	10.02 - Genomic HLA homozygosity is frequent in esophageal adenocarcinoma and related to low immunogenicity Maria Garcia-Marquez, Cologne, Germany
14.10 – 14.30	10.03 - Interleukin-22 regulates anti-tumor immunity in mouse models of lung and breast carcinoma Daria Briukhovetska, Munich, Germany
14.30 – 14.50	10.04 - A library of novel Cancer Testis specific T-cell receptors for T-cell receptor gene therapy Marije de Rooij, Leiden, Netherlands
14.50 – 15.20	Coffee Break
15.20 – 16.40	Session 11: Combination Therapy Chair: Michael Bergmann and Wenru Song
15.20 – 15.40	11.01 - Cancer-specific nanoparticle-based Photodynamic/photothermal therapy synergizes immunotherapy in bladder cancer Chong-Xian Pan, Boston, MA, USA
15.40 – 16.00	11.02 - Systemic effects of local administration of anti-CTLA4 in early-stage melanoma Tanja de Gruijl, Amsterdam, The Netherlands
16.00 – 16.20	11.03 - Novel molecular and immune mechanisms to enhance radiation + checkpoint immunotherapy Jason Luke, Pittsburgh, PA, USA
16.20 – 16.40	11.04 - CD40 Combinations Gregory L. Beatty, Philadelphia, PA, USA
16.40 – 17.00	Session 12: Best Poster Awards & Closing Remarks Chair: Volkmar Nüssler and Sebastian Kobold



P1 - Emerging concepts / novel agents

P01.01 Safety and Efficacy Study of Pembrolizumab in Combination With LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant as Neoadjuvant Therapy——PLENTY Randomized Clinical Trial

Presenting Author: Hao Feng, Shanghai, China

P01.02 TLR-mediated suppression of the CCL22-CCR4 axis as a new target for tumor immunotherapy

Presenting Author: Juliane Grün, München, Germany

P01.03 Targeting Diacylglycerol Kinase alpha and zeta by self delivering RNAi to optimize Tlymphocytes for adoptive therapy of solid tumors

Presenting Author: Anna Herbstritt, Munich, Germany

P01.04 Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia

Presenting Author: Ramya Nair, Munich, Germany

P01.05 Deciphering the function of the ubiquitin-proteasome-system in regulating the immune checkpoint protein B7-H3 (CD276) in non-small cell lung cancer

Presenting Author: Marisa Kurz, Munich, Germany

P01.06 Overweight and obesity as biomarkers for survival outcomes and immune related adverse events undergoing immunotherapy - a systematic review and meta-analysis

Presenting Author: Paul Trinkner, Munich, Germany

P01.07 Depletion of CD206high tumour-associated macrophages using a nanoconjugate limits tumour burden & dissemination in metastatic triple negative breast cancer in mice

Presenting Author: Anni Lepland, Tartu, Estonia

P01.08 Sarcopenia as biomarker for immunotherapy outcomes and immune-related adverse events - a systematic review and meta-analysis

Presenting Author: Sophie Günther, München, Germany

P2 - Tumor microenvironment and microbiome in Immunotherapy

P02.01 T- and B-cell abundance are remarkably reduced in the immune microenvironment of post-transplant malignancies

Presenting Author: Simon Schran, Cologne, Germany

P02.02 Single-cell RNA sequencing of neuroblastoma tumors reveals immunoregulatory interactions as novel targets for immunotherapy

Presenting Author: Judith Wienke, Utrecht, Netherlands

P02.03 Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers.

Presenting Author: Niclas Blessin, Hamburg, Germany



POSTER PRESENTATIONS

P02.04 Tissue-Infiltrating Th9 cells in Human endometrial Cancer

Presenting Author: Huan Tong, Shanghai, China

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-small Cell Lung Cancer at Single Cell Resolution

Presenting Author: Yuan Cordts, Cologne, Germany

P02.06 Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence

Presenting Author: Niclas Blessin, Hamburg, Germany

P02.07 Characterization of the tumor immune microenvironment of pediatric posterior fossa A ependymomas

Presenting Author: Julie Lammers, Utrecht, Netherlands

P02.08 The Role of FoxP3+ Regulatory T Cells and IDO+ Immune and Tumor Cells in Malignant Melanoma - an immunohistochemical study

Presenting Author: Satu Salmi, Kuopio, Finland

P02.09 Heteromerization of uPA and PAI-1 enforces pro-tumorigenic neutrophil trafficking to malignant tumors in breast cancer via VLDLr-dependent $\beta 2$ integrin clustering

Presenting Author: Bernd Uhl, München, Germany

P02.10 FocuSCOPE: A single cell, multi-omics solution to simultaneously analyze tumor variants and microenvironment

Presenting Author: Yasaman Arjmand Abbassi, Köln, Germany

P02.11 TREM1 agonist PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity

Presenting Author: Vladi Juric, South San Francisco, United States

P3 - Vaccine Therapy

P03.01 High immunogenic VLP-based vaccines elicit new T cell specificities against melanoma neoantigens in mice

Presenting Author: Carmen Aguilar-Gurrieri, Badalona, Spain

P03.02 Protein-based cancer vaccine combined with an oncolytic vaccine promotes potent antitumor immunity

Presenting Author: Elodie Belnoue, Geneva, Switzerland


P03.03 Novel machine-learning tools improve cost-effective development of personalised immunotherapies: lowering false positive rates in the search for actionable immunogenic neoantigens

Presenting Author: Lore Van Oudenhove, Ghent, Belgium

P03.04 Novel algorithm discovers up to 35 percent more epitopes translated from non-coding regions in cold tumours

Presenting Author: Lore Van Oudenhove, Ghent, Belgium

P03.05 Withdrawn



P03.06 Deciphering vaccine-induced neoepitope-specific T cell responses in a patient with H3K27M-mutant midline glioma WHO grade 4
Presenting Author: Katharina Lindner, Heidelberg, Germany

P03.07 Analysis of scRNAseq from the human thymus nominates genes potentially missing from central tolerance of cytotoxic T cells
Presenting Author: Lili Blumenberg, Tarrytown, United States

P4 - Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

P04.01 Immunomonitoring of CD19. CAR T-cells in Large B-Cell Lymphoma- a two-center experience
Presenting Author: Viktoria Blumenberg, Munich, Germany

P04.02 Diversity of CD4+ blood T-cell clonality predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma
Presenting Author: Akiko Arakawa, München, Germany

P04.03 Expression profiles of immune markers as predictors of survival in surgically-treated NSCLC
Presenting Author: Laura Sellmer, Munich, Germany

P04.04 Programmed death-ligand 1 positron emission tomography imaging during neoadjuvant (chemo)radiotherapy in esophageal and rectal cancer (PETNEC): a prospective non-randomized open-label single-center pilot study
Presenting Author: Johannes Laengle, Vienna, Austria

P5 - "Lost in Translation"?

P05.01 Organoid-specific optimization of killing assays to test novel immunotherapies in a high-throughput system
Presenting Author: Femke van den Ham, Utrecht, Netherlands

P6 - Cell Therapy in Solid Tumors

P06.01 $\alpha\beta$ -T cells engineered to express $\gamma\delta$ -T cell receptors can kill neuroblastoma organoids independent of MHC-I expression
Presenting Author: Josephine Strijker, Utrecht, Netherlands

P06.02 Cancer-specific differences of tertiary lymphoid structures and cellular responses against frequently expressed cancer testis antigens
Presenting Author: Ella Preugszat, Cologne, Germany

P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models
Presenting Author: Mohamed-Reda Benmebarek, Munich, Germany

P06.04 Transcriptome-wide network analysis predicts the role of lactate dehydrogenase C in breast cancer cell survival and immune dysfunction
Presenting Author: Adviti Naik, Doha, Qatar

P06.05 Endogenous T-cell responses to ten major cancer testis antigens are frequent in esophago-gastric adenocarcinoma and antigen-specific T cells can be expanded using CD40-activated B cells
Presenting Author: Martin Thelen, Cologne, Germany



POSTER PRESENTATIONS

P06.06 Enhancing trafficking and resistance to immunosuppression of synthetic agonistic receptor-transduced T cells in solid tumor models

Presenting Author: Melanie Schwerdtfeger, Munich, Germany

P06.07 In vivo studies of immunomodulatory α -CTLA-4 antibody in a humanized mouse model

Presenting Author: Carmen Reitingner, Erlangen, Germany

P7 - Cell Therapy in Haematologic Diseases

P07.01 A modular and controllable T cell therapy platform for AML

Presenting Author: Mohamed-Reda Benmebarek, Munich, Germany

P07.02 Regulation of CD19 CAR T- cell activation based on engineered Nuclear factor of activated T cells artificial transcription factors

Presenting Author: Duško Lainšček, Ljubljana, Slovenia

P07.03 "myTcell": A smartphone application guides logistics and management of CAR T-cell G- BiTE related toxicities

Presenting Author: Viktoria Blumenberg, Munich, Germany

P8 - Combination Therapy

P08.01 Rationale of using the combination of anti-PD-1 antibody and anti-IL-8 antibody for the pancreatic cancer treatment

Presenting Author: Jessica Gai, Baltimore, United States

P08.02 CCR2/CCR5 dual-antagonist "licenses" the radiation-induced effector T-cell infiltration in the anti-PD-1 antibody-treated pancreatic adenocarcinoma

Presenting Author: Jianxin Wang, Hangzhou, China

P08.03 Neoantigen cancer vaccine augments anti CTLA-4 efficacy

Presenting Author: Fabio Palombo, Rome, Italy

P08.04 Successful immunotherapy of the breast cancer metastatic disease in mice using a pharmaceutical TLR4-agonist induces systemic anti-tumor T cell response and long-term T cell memory

Presenting Author: Ekaterina Ushakova, Moscow, Russian Federation

P08.05 Combined pharmacological targeting of adenosine 2a- and 2b-receptor enhances CAR T cell function

Presenting Author: Matthias Seifert, Munich, Germany


P08.06 Combining RIG-I-targeted immune activation with CAR T cell therapy induces efficient tumor control in murine pancreatic cancer models

Presenting Author: Anne Senz, München, Germany

P9 - Young Researcher Session

P09.01 The use of FDA approved JAK, mTOR and Src inhibitors to regulate T cell-bispecific antibody-induced cytokine release while not preventing T cell cytotoxicity.

Presenting Author: Gabrielle Leclercq, Schlieren, Switzerland



POSTER PRESENTATIONS

P09.02 Epigenetic modulation of neuroblastoma enhances T- and NK cell immunogenicity via induction of surface expression of MHC class I and MICA/MICB

Presenting Author: Annelisa Cornel, Utrecht, Netherlands

P09.03 Hyaluronic acid as a new immunologic adjuvant in cancer: design of effective preventive and therapeutic vaccination strategies for HER2/neu-positive breast tumors

Presenting Author: Debora Carpanese, Padova, Italy

P09.04 Impact of major oncologic surgery on immune responses in the immediate post-operative setting in oesophageal adenocarcinoma patients; a guide to harnessing the double-edged sword of cancer surgery

Presenting Author: Noel Donlon, Dublin, Ireland

P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer

Presenting Author: Ikuan Sam, Paris, France

P09.06 Investigating various patient parameters as prognostic markers for patients with advance stage nasopharyngeal carcinoma undergoing induction chemotherapy followed by Epstein-Barr virus cytotoxic T-lymphocyte immunotherapy

Presenting Author: Axel Jun Ming Chu, Singapore, Singapore

P09.07 Novel insights into immune-independent functions of immune checkpoint inhibitors in oesophageal adenocarcinoma; potential implications for designing combination immuno-chemotherapy regimens to achieve synergistic responses

Presenting Author: Maria Davern, Dublin, Ireland



SCIENTIFIC INFORMATION

Session Structure for Live Presentations

All sessions include pre-recordings as well as a live component. We want to make sure to retain as much human interaction as possible. Prior to the sessions, all lectures are recorded and uploaded to our system. They need to be of an exact length to ensure smooth development of the sessions. At the scheduled timeslot of the session, the chairperson of the session will open the session and introduce the speakers. Then the recording of the first lecture will be played. At all times there is a live-chat available, where all participants can contribute to the session or ask questions which will be monitored by the moderator. After each lecture, there is some time reserved for a discussion with the chairpersons. Lecturers and chairpersons therefore are online at the scheduled timeslot and will discuss questions raised by the audience in the live chat.

Commercial Disclosure information

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

Speaking Time

The chairpersons of live sessions will be strict in allowing no more than the time allotted to discussions following the pre-recorded presentations. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.


On-Demand Symposia & e-Poster Presentations

On-Demand Symposia and e-Poster Presentations can be viewed by participants "on-demand", which means that individual presentations do not have dedicated times at which they can be viewed – they can be viewed at any time. Authors of e-Poster presentations can be contacted via a messaging system on the conference platform as of October 8, 2021.

Availability of presentations after the Conference

All On-Demand Symposia and e-poster presentations will be available (for registered participants only) on the virtual platform on the conference days and remain there for review until November 9, 2021 at 23.59 CEST.

All live presentations will be available for an on-demand review after October 9, 2021 and remain available there (for registered participants only) until November 9, 2021 at 23.59 CEST



Friday, October 8, 2021

12.50 - 13.20 hrs

10x Genomics Satellite Symposium

Introduction & Moderation:

Amelie Castro, 10x Genomics

Immune Cell and Repertoire Profiling at Single Cell Resolution

Koen Deglas, Leuven, Belgium



10x Genomics offers a selection of products to meet the challenges of immunological studies that have the flexibility to be integrated with your current flow cytometry workflow. Our Single Cell Immune Profiling and Gene Expression solutions with Feature Barcode technology enable you to perform multiomic phenotyping in thousands of single immune cells, including cell surface protein and antigen specificity characterization, and can be combined with adaptive immune repertoire and gene expression analysis. Together, these solutions are enabling researchers to gain a clear, holistic view of the immune system and address complex questions that have evaded previous technologies.



LIVE SATELLITE SYMPOSIA

Friday, October 8, 2021

17.20 - 17.50 hrs

NanoString Technologies Satellite Symposium

Tackling Cancer Research Challenges with Spatial Biology.

Introduction & Moderation:

Agnese Winfield, Bristol, UK

Panelists:

Dana Mustafa, Rotterdam, The Netherlands


Sarah Warren, Seattle, USA

Nina Radsevich, Clermont-Ferrand, France



Join our Spatial Panelists to discuss some of the solutions to the biggest cancer research challenges:

- How to decipher the interactions between the tumor and microenvironment with Spatial Biology and manage immune evasion.
- How to leverage critical organ specific markers to understand the highly heterogeneous cancers types with variable therapeutic response.
- How can Spatial Biology accelerate our understanding of the ever-increasing number of possible therapeutic targets and combination trials



Vision Zero Satellite Symposium

VISION-ZERO E.V. - TOGETHER AGAINST CANCER

AN INITIATIVE FOR A NEW APPROACH IN ONCOLOGY

Daniel Bahr, München; Dr. Ruth Hecker, Essen, Prof. Dr. Dr. Michael von Bergwelt, München, Dr. Georg Ralle, München



VISION STATEMENT

We are committed to bringing the number of avoidable deaths from cancer close to zero.

For years, the statistics have painted the same sad picture: in Germany, around every fourth citizen dies from cancer – that's 600 people per day, 220,000 per year. But a large number of these deaths could be avoided through better prevention and early detection, more precise diagnostics, the faster transfer of therapeutic innovations into practice, and access to care across the country that conforms to the guidelines and is individually optimised. Our goal is therefore to make sure that the potential held in these approaches is fulfilled and consequently to reduce the number of avoidable deaths from cancer significantly - ideally to zero. This "Vision Zero" is based on extraordinarily successful models in the fields of worker safety and in road traffic; over the past decades, the number of road deaths has been reduced by 90%, even as traffic has greatly increased. We believe that we can be just as successful in oncology and that cancer does not have to be one of the main causes of death in the future if we join forces and focus on this issue.

More information coming soon

Sico Biological Satellite Symposium



Strategies and challenges for generation of high-quality antibodies-Sino Biological Inc.

Zhang Linlin, Eschborn, Germany

Sino Biological is an international reagent supplier and service provider. The company is dedicated in providing the scientific community with high-quality recombinant protein and antibody reagents to facilitate life science research and drug discovery.

Sino Biological has the biggest validated recombinant protein bank (6000+) and was the first company in the world that expressed SARS-CoV-2 antigens, which still has the most complete line of COVID19-related products so far.

To advance immunological studies, our high-quality products have covered most Cytokines and Growth Factors, Fc Receptors, CAR-T Cell Therapy Targets and Immune Checkpoint Proteins. All our products are independently developed and manufactured, including recombinant proteins, antibodies and cDNA clones.

We are a one-stop technology store for researchers with the advanced technology platforms they need to make advancements. As a leading recombinant protein and antibody manufacturer, we also provide customized CRO services for recombinant production of proteins and antibodies, as well as for traditional antibody development, to our global academic, biotech and biopharma customers, with over 5000 projects completed.

Sino Biological Europe GmbH sits in Frankfurt, Germany, with a local sales and service team, and an inventory of our product.



GENERAL INFORMATION



In alphabetical order.

Cancellations and Refunds

Registration fees may be refunded if written cancellation has been received as follows:

- until June 1, 2021: full refund
- from June 2, 2021 to August 1: 50% refund
- as of August 2, 2021: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering for ITOC8, participants agree that neither the organising committee nor the Congress Office assume any liability whatsoever.

Refunds will be made after October 9, 2021

Certificate of Attendance

Confirmations of attendance will be issued to all registered participants after completion of an online survey.

CME Credits

The "8th ImmunoTherapy of Cancer Conference" taking place virtually was granted a total of 11 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Functionality of the virtual platform

The conference organiser's subcontractors provide a high level of availability of their network, cannot however give any guarantee that their network will operate without any interruptions or malfunctions. No assurances or guarantees can be given about the availability, quality, operation or support services for data traffic, on the networks, or lines of the participant's Internet provider. The conference organiser is not liable if the provision of the services is interrupted, partially restricted, or impossible as a result of force majeure. Force majeure is for example considered natural phenomena of significant intensity (avalanches, floods, etc.), conflicts, terrorism, strikes, unexpected official restrictions, power cuts, computer viruses, worms, Trojan horses etc.

Language

The official language of the conference is English (no simultaneous translation).

Liability


In registering for ITOC8, participants agree that neither the organising committee nor the Congress Office assume any liability whatsoever. The organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Virtual Conference

October 8, 2021: 08.00 – 18.30 hrs CEST

October 9, 2021: 08.00 – 17.00 hrs CEST

All Live Talks, On-Demand Symposia and e-Poster presentations will be available for review after the conference as of October 9, 2021 until November 9, 2021 at 23.59hrs CEST.



In alphabetical order.

Presentations

All presenters are requested to upload their pre-recorded presentations on the virtual platform until September 22, 2021. Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts. If you have nothing to disclose, please state "I have no commercial disclosure" instead of the table.

Registration Details

Registration Fees in EUR (all fees include 20% Austrian VAT)

	from February to September 8, 2021	from September 9, 2021
Academia	EUR 220,-	EUR 240,-
Junior Participant ⁽¹⁾	EUR 120,-	EUR 140,-
Industry	EUR 320,-	EUR 340,-

⁽¹⁾ The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration either by fax to +43 1 405 13 83 918 or upload a jpeg, jpg, gif, bmp or png

Payments should be made without charges to the beneficiary. Any bank charges will be claimed. Clearly state the participant's name(s) and the invoice number on the bank transfer.

Please be informed, that due to the virtual conference format, Creditcard payment is preferred.

As of October 1, 2021 ONLY creditcard payment will be possible. Thank you for your understanding.

What is covered by the registration fee?

Admission to all scientific sessions (Live, e-Poster, On-Demand)

Abstract book and programme (both online)

Cancellations:

Please note that only written cancellations addressed to ITOC c/o Vienna Medical Academy GmbH, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:

- until June 1, 2021: full refund
- from June 2, 2021 to August 1: 50% refund
- as of August 2, 2021: no refund

Twitter

The 8th ImmunoTherapy of Cancer Conference is present on Twitter @ITOCconference.

We invite you to follow us on Twitter and to engage and discuss with your colleagues.



ACKNOWLEDGEMENTS



The organisers gratefully acknowledge the support of the following institutions and companies:



Supported by grants from



Pfizer Inc.





THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY
CONFERENCE IN EUROPE

CONFERENCE MANAGEMENT

WMA GmbH
Catherine Tomek
itoc@medacad.org

SPONSORING MANAGEMENT

Rose International
Flora van Laer
fvanlaer@rose-international.com

www.itoc-conference.eu